<DOC>
	<DOCNO>NCT00224393</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Enbrel patient primary systemic Amyloidosis .</brief_summary>
	<brief_title>Phase II Trial Enbrel Patients With Primary Systemic Amyloidosis</brief_title>
	<detailed_description>The primary goal study evaluate efficacy Enbrel patient primary systemic amyloidosis use one-stage , phase II study design interim analysis . This study also assess survival progression time , symptom relief , toxicity associate Enbrel primary systemic amyloidosis patient . Two group patient different risk profile identify respect disease . Patients symptomatic cardiac disease and/or least two involved organ ar high risk historically median survival less six month . Patients without condition significantly good prognosis . Both subgroup study present study , essentially two phase-II clinical trial , one subgroup , run parallel .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>&gt; =18 year age . Laboratory value obtain &lt; =14 day prior registration . No limitation cardiac ejection fraction Bilirubin &lt; 3 mg/dL Absolute neutrophil count &gt; =500/microliters Histochemical diagnosis amyloidosis base detection polarize microscopy green birefringent material Congo redstained tissue specimen characteristic electron microscopy appearance . Demonstrable Mprotein serum/urine clonal population plasma cell bone marrow immunohistochemical stain antilight chain antiserum amyloid fibril . ECOG performance status 0 , 1 , 2 , 3 . Symptomatic organ involvement amyloid justify therapy . This could include liver involvement , cardiac involvement , renal involvement , peripheral neuropathy , soft tissue involvement . Must purpura carpal tunnel syndrome . Previously treat untreated . No limit prior therapy provide adequate residual organ function . Ability provide inform consent . Ability selfinject medication caregiver administer drug . Amyloidspecific syndrome , , carpal tunnel syndrome skin purpura evidence disease . The finding vascular amyloid bone marrow biopsy specimen plasmacytoma indicative systemic amyloidosis . Presence nonAL amyloidosis . Melphalan alkylating agent , highdose dexamethasone alpha interferon &lt; =4 week prior registration . Concurrent use corticosteroid , patient may chronic steroid give disorder amyloid , i.e. , adrenal insufficiency , rheumatoid arthritis , etc . Any following : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception ( condom , diaphragm , birth control pill , injection , intrauterine device [ IUD ] , surgical sterilization , abstinence , etc . ) Uncontrolled infection . Clinically overt multiple myeloma ( monoclonal BMPC &gt; 30 % ) , least one following : Bone lesion Hypercalcemia Active malignancy exception adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated Stage I II cancer patient currently complete remission , cancer patient diseasefree 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Amyloidosis</keyword>
	<keyword>Enbrel</keyword>
</DOC>